Thyroid Cancer clinical trials
49 active trials name this condition (recorded in the registry as “Thyroid Gland Carcinoma”) . Describe your situation to see which ones you may be eligible for.
By location
- Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
- Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- TRAIL Study: Feasibility and Pilot
- Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
- A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients
- Personalized Treatment in Thyroid Disorders
- An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
- Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
- Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
- Hereditary Risk Factors for Thyroid Cancer
- The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- Studies on Tumors of the Thyroid
- I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
- Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
- A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
- Environmental Factors and Thyroid Cancer
- Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
- New MRI Biomarkers in Head and Neck Cancers
- Navigation Intervention for Adolescent and Young Adult Cancer Survivors
- Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
- DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
- DESTINY-PANTUMOUR04
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Liquid Biopsies in Pediatric Solid Tumors
- International PPB/DICER1 Registry
- Integrated Cancer Repository for Cancer Research
- Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery
- Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
- Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
- Active Surveillance of Papillary Thyroid Microcarcinoma
- A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
- Improving Care for Rural Patients With Solid Tumors
- Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
- Decision Aid Efficacy in Low Risk Thyroid Cancer
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
- Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
- Quest to Analyze One Thousand Humans Meditating
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
- Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Thyroid Gland Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.